| Multiple Myeloma

Tecvayli vs Xgeva

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Tecvayli vs Xgeva with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsXgeva has a higher rate of injection site reactions vs Tecvayli based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Xgeva but not Tecvayli, including UnitedHealthcare

Category

Tecvayli

Xgeva

At A Glance

RouteSC injection

FrequencyWeekly to every 4 weeks

ClassBCMA-directed CD3 T-cell engager

RouteSC injection

FrequencyEvery 4 weeks

ClassRANKL inhibitor

Indications

Multiple Myeloma

Multiple Myeloma
Metastatic malignant neoplasm to bone
Giant Cell Tumor of Bone
Humoral hypercalcemia of malignancy (disorder)

Dosing

Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.

Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.

Multiple Myeloma, Metastatic malignant neoplasm to bone 120 mg SC every 4 weeks in the upper arm, upper thigh, or abdomen.

Giant Cell Tumor of Bone, Humoral hypercalcemia of malignancy (disorder) 120 mg SC every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy, in the upper arm, upper thigh, or abdomen.

Contraindications

—

Pre-existing hypocalcemia
Known clinically significant hypersensitivity to Xgeva or denosumab products

Drug Interactions

27View drug interactions

378View drug interactions

Adverse Reactions

Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased

Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy

Most common (>=25%) Fatigue/asthenia, hypophosphatemia, nausea

Serious Dyspnea, osteonecrosis of the jaw, hypocalcemia, atypical subtrochanteric and diaphyseal femoral fracture, multiple vertebral fractures following treatment discontinuation

Postmarketing Severe symptomatic hypocalcemia (including fatal cases), severe symptomatic hypercalcemia following treatment discontinuation, hypersensitivity including anaphylactic reactions, severe musculoskeletal pain, lichenoid drug eruptions, alopecia

Pharmacology

Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.

Xgeva is a RANKL inhibitor; it binds to RANKL, a protein essential for osteoclast formation, function, and survival, thereby preventing osteoclast-mediated bone resorption and modulating calcium release from bone in solid tumor bone metastases, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Tecvayli